General Medicine Raises $120 Million Series B for Online Healthcare Store

Who invested and what the company sells

According to the company's announcement, the round included participation from Matrix, VXI Capital, Eli Lilly and Company, Mercy Health through Granger Management, and BoxGroup. Vineeta Agarwala, MD, PhD, General Partner at a16z, led the investment.

General Medicine says customers can search, compare and buy care, and see what it costs with and without insurance before deciding. The catalog now includes more than 2,900 products and services across medications, labs, telehealth, specialist e-consults, and select in-person visits and procedures. The company says it is open nationwide.

It was founded in 2023 and launched nationwide in May 2025. According to the company, it organizes care around what customers need rather than around medical specialties or institutional structures.

Usage figures and how the store works

General Medicine reports several figures since launch. Hundreds of thousands of customers have signed up across the country, with an NPS average of 80. The company says 83% of customers told it that it helped them address a health need they had been putting off, and a third had delayed care for more than six months. The average customer's health record spans 11 years and is presented to clinicians as a prioritized summary at the time of care. These numbers come from the company itself.

The store rests on a product catalog that reconciles how customers, clinicians, insurers, laboratories and health systems may each describe the same service differently. According to the company, that common definition makes pricing, comparison and clinical matching possible.

Customers can use three routes:

• Search, compare and purchase care directly when they know what they need.
• Talk with a licensed clinician, usually available the same day, for a recommendation.
• Use the AI chat to explore symptoms or goals and understand their options.

Health history and context carry across each path, and a licensed clinician determines what is clinically appropriate whenever clinical review is required. The company also states that investor and commercial relationships do not determine which products customers see or which treatments clinicians recommend.

Plans, AI agents and leadership change

General Medicine will use the new funding to expand its store into more categories of care. The company also points to AI agents: the same infrastructure that lets a customer shop today, it says, will allow an AI agent to shop on someone's behalf.

CEO TJ Parker framed the pitch this way: "Everyone's building a healthcare AI agent that can tell you what you might need. What's missing is the infrastructure that lets you actually get it."

Parker joined General Medicine full time as CEO in October 2026. He was previously a General Partner at Matrix, where he led the company's early funding rounds, and he has served on its board since its founding. He continues as a Venture Partner at Matrix. Ashwin Muralidharan, the founding CEO, moved into the Chief Product Officer role, where he continues to lead product, engineering, design, clinical, operations and much of the business day to day. Elliot Cohen is President.

What it means for patients and the market

The company's argument is that price transparency shifts the balance of power. Cohen said that when a customer can see options and price, "the rest of the system has to compete," whether that is a payer, a health system or a drug manufacturer.

Agarwala of a16z said General Medicine "has built one of the best patient experiences we've seen in the market." For consumers, the offer is a single place to see insurance and cash prices and reach a clinician. How far the model scales across more categories of care is what the new funding is meant to test.